IgG3 is the dominant subtype of anti-isoniazid antibodies in patients with isoniazid-induced liver failure.

Abstract

Isoniazid (INH) therapy is associated with a significant incidence of idiosyncratic liver failure. We recently reported eight cases of INH-induced liver failure in which patients had antidrug and anticytochrome P450 antibodies. However, it was unclear what role these antibodies play in the mechanism of INH-induced liver injury. Here, we report that the dominant isotype of anti-INH antibodies was IgG, with IgG3 being the dominant subtype. IgG3 antibodies are associated with a Th1-type immune response and fix complement. IgG3 antibodies have been associated with other forms of liver injury and may play a pathogenic role in INH-induced liver injury.

• Authors: Imir G Metushi, William M Lee, Jack Uetrecht
• Journal: Chemical research in toxicology (Chem Res Toxicol) Vol. 27 Issue 5 Pg. 738-40 (May 19 2014) ISSN: 1520-5010 [Electronic] United States
• PMID: 24786179 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antitubercular Agents
• Immunoglobulin G
• Isoniazid

Topics

• Antitubercular Agents (adverse effects, immunology)
• Chemical and Drug Induced Liver Injury (blood, immunology, pathology)
• Humans
• Immunoglobulin G (immunology)
• Isoniazid (adverse effects, immunology)
• Liver (drug effects, immunology, pathology)
• Liver Failure (blood, chemically induced, immunology, pathology)